Table 1.
A list of current clinical trials, disease status of patients being enrolled, and central nervous system exclusion criteria for patients diagnosed with blastic plasmacytoid dendritic cell neoplasm.
| Trial Identifier | Agents | Eligible Patients | Exclusion CNS Criteria |
|---|---|---|---|
| NCT03485547 | Venetoclax | BPDCN | None |
| NCT03113643 | TAG + Azacitidine/Azacitidine and Venetoclax | Relapsed/refractory BPDCN | Yes |
| NCT02159495 | Autologous/Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes | Relapsed/refractory BPDCN after first-line therapy | None—Lymphodepletion for IT |
| NCT04230265 | UniCAR02-T Cells | BPDCN | Yes |
| NCT03386513 | IMGN632 | BPDCN | Yes |
| NCT04109482 | MB-102 | Relapsed/Refractory BPDCN | Yes |
| NCT04317781 | TAG | BPDCN post-HSCT | Yes |
| NCT04216524 | Venetoclax + TAG + Cyclophosphamide + Cytarabine + Doxorubicin + Mercaptopurine + Methotrexate + Rituximab + Vincristine | BPDCN | Yes |
| NCT03599960 | Idarubicin + Methotrexate + L-asparaginase + Dexamethasone followed by allo- or auto-SCT or Methotrexate + L-asparaginase + Dexamethasone | BPDCN | None |
| NCT03404193 | Venetoclax + Decitabine | BPDCN | Partial |